IMMX (Immix Biopharma) FCF Yield %: -4.02 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMX Immix Biopharma Inc IMMX
22 GF Score
Price $13.67
! 2 Warning Signs
View Full Analysis

What is Immix Biopharma FCF Yield %?

Immix Biopharma IMMX +3.80% 22 FCF Yield % is -4.02 as of Aug. 23, 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Immix Biopharma ranks better than 66.6% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Immix Biopharma's Trailing 12-Month Free Cash Flow is $-39.09 Mil, and Market Cap is $972.81 Mil. Therefore, Immix Biopharma's FCF Yield % for today is -4.02%.

The historical rank and industry rank for Immix Biopharma's FCF Yield % or its related term are showing as below:

IMMX' s FCF Yield % Range Over the Past 10 Years
Min: -4.02   Med: 0   Max: 0
Current: -4.02


IMMX's FCF Yield % is ranked better than
66.6% of 1410 companies
in the Biotechnology industry
Industry Median: -9.28 vs IMMX: -4.02

Immix Biopharma's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.


Immix Biopharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Immix Biopharma FCF Yield % Related Terms


Immix Biopharma FCF Yield % Historical Data

* Premium members only.

The historical data trend for Immix Biopharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma FCF Yield % Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial -3.38 -23.29 -8.29 -26.03 -8.91

Immix Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.99 -36.37 -16.17 -8.17 -6.41

IMMX vs CBIO, NVCT, ALLO: FCF Yield % Comparison

For the Biotechnology subindustry, Immix Biopharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's FCF Yield % falls into.


IMMX
22GF Score
Immix Biopharma Inc IMMX
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immix Biopharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Immix Biopharma's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-24.663 / 276.93373
=-8.91%

Immix Biopharma's annualized FCF Yield % for the quarter that ended in Jun. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-11.757 * 4 / 733.9689
=-6.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -4.02 mean?
Immix Biopharma (IMMX) has a FCF Yield % of -4.02 as of Aug. 23, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Immix Biopharma and its competitors. According to the industry distribution chart, Immix Biopharma ranks #471 out of 1410 companies in the Biotechnology industry, placing it in the top 33.4%.
Is Immix Biopharma's FCF Yield % too high?
Immix Biopharma's current FCF Yield % is -4.02. Based on the distribution chart, Immix Biopharma ranks #471 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's FCF Yield % compare to CBIO and NVCT?
According to the Biotechnology industry distribution chart, Immix Biopharma ranks #471 out of 1410 companies for FCF Yield %. This puts Immix Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Immix Biopharma and its competitors. Immix Biopharma's current FCF Yield % is -4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current FCF Yield % of -4.02. The current FCF Yield % is -4.02. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current FCF Yield % is -4.02 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immix Biopharma Business Description

Address 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score

Get the complete analysis for IMMX

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price